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Encapsulating peritoneal sclerosis (EPS) is a devastating but, fortunately, rare complication
of long-term peritoneal dialysis. The disease is associated with extensive thickening and
fibrosis of the peritoneum resulting in the formation of a fibrous cocoon encapsulating
the bowel leading to intestinal obstruction. The incidence of EPS ranges between 0.7
and 3.3% and increases with duration of peritoneal dialysis therapy. Dialysis fluid is
hyperosmotic, hyperglycemic, and acidic causing chronic injury and inflammation in the
peritoneum with loss of mesothelium and extensive tissue fibrosis. The pathogenesis of
EPS, however, still remains uncertain, although a widely accepted hypothesis is the “two-
hit theory,” where, the first hit is chronic peritoneal membrane injury from long standing
peritoneal dialysis followed by a second hit such as an episode of peritonitis, genetic
predisposition and/or acute cessation of peritoneal dialysis, leading to EPS. Recently, EPS
has been reported in patients shortly after transplantation suggesting that this procedure
may also act as a possible second insult. The process of epithelial–mesenchymal transition
of mesothelial cells is proposed to play a central role in the development of peritoneal
sclerosis, a common characteristic of patients on dialysis, however, its importance in EPS
is less clear. There is no established treatment for EPS although evidence from small case
studies suggests that corticosteroids and tamoxifen may be beneficial. Nutritional support
is essential and surgical intervention (peritonectomy and enterolysis) is recommended in
later stages to relieve bowel obstruction.
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INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a chronic clinical syn-
drome of insidious onset, presenting late as chronic malnourish-
ment with signs and symptoms of intermittent, acute or sub-acute
gastrointestinal obstruction (Augustine et al., 2009). It appears
to be a multifactorial disease with several initiating factors that
are significant at the different stages of the disease. Diagnosis
is confirmed by macroscopic and/or radiological observation of
sclerosis, calcification, peritoneal thickening or encapsulation of
the intestines (Kawaguchi et al., 2000). EPS can be fatal but, for-
tunately, it is a rare complication predominantly of long-term
peritoneal dialysis (PD). Since the first case of EPS was reported
in 1980 (Gandhi et al., 1980), there has been a steady rise in the
incidence of the disease from 0.9% in 1996 to 3.3% in 2005 as
patients stay on PD for longer and awareness of this complication
has increased. The data obtained over the years from several ret-
rospective studies performed to investigate this potentially fatal
condition estimate the worldwide incidence of EPS at 0.7–3.3%
in patients on PD (Brown et al., 2009). The mortality rate for
patients with EPS is great at 25–55%, predominately in the year
after diagnosis and is directly proportional to the duration of
PD treatment (Rigby and Hawley, 1998; Kawanishi et al., 2004;
Kawanishi and Moriishi, 2005; Brown et al., 2009).
AETIOLOGY
EPS is usually seen in end-stage renal disease (ESRD) patients
who have been on long-term PD therapy. Dialysis fluid is dam-
aging to the peritoneum due to the high glucose concentration
and acidic pH. A high glucose concentration facilitates the osmo-
sis and diffusion gradient across the peritoneum and the low pH
acts to prevent the formation of glucose degradation products
(GDPs) which are damaging agents (Jorres et al., 1992). Heat ster-
ilization of PD fluid leads to the formation of GDPs (Wieslander,
1996) and these in the presence of glucose cause the forma-
tion of advanced glycation end products (AGEs) (Mortier et al.,
2002). More biocompatible solutions are now being used that
contain less GDPs which results in reduced peritoneal damage
(Boulanger, 2008).
Interestingly, EPS can also develop in patients not on PD
but associated with other conditions such as autoimmune dis-
eases, sarcoidosis, peritoneal and intra-abdominal malignan-
cies, chronic peritoneal ascites, intra-peritoneal chemotherapy,
intraperitoneal exposure to particulate matter or disinfectant,
abdominal surgery, endometriosis, intra-peritoneal infections
(tuberculosis), and beta-blocker administration (Pollock, 2001;
Kawanishi and Moriishi, 2005) (Table 1). Chronic renal failure
itself could also induce peritoneal changes including thickening
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before PD therapy (Williams et al., 2002) and uremia, a con-
tributory factor in all PD patients, is known to lead to a pro-
inflammatory state (Baroni et al., 2012).
RISK FACTORS
The duration of PD therapy seems to be the most important risk
factor for the development of EPS. In an Australian survey, the
incidence of EPS increased with the duration of PD, being 1.9,
6.4, 10.8, and 19.4% in patients on PD for more than 2, 5, 6, and
8 years respectively (Rigby and Hawley, 1998).
A Japanese prospective study reported similar findings, in
which the incidence of EPS was 0.7% after 5 years, 2.1% after 8
years, 5.9% after 10 years, and 17.2% after 15 years of PD ther-
apy (Kawanishi et al., 2004). A more recent Scottish study also
reported an increase in incidence of EPS from 2% at 2–3 years to
8.8% at 5–6 years of PD therapy (Brown et al., 2009). However,
most cases of EPS are diagnosed after discontinuation of PD ther-
apy. A Japanese prospective study reported that 69% of EPS cases
occurred after discontinuation of PD therapy (Kawanishi et al.,
2004). This suggests that despite PD being a major risk factor for
EPS, lavage of the peritoneal cavity during PD may possibly limit
the accumulation of factors that encourage the development of
the disease (Yamamoto et al., 2005, 2010).
Interestingly, organ transplantation appears to increase the
risk of developing EPS as some studies have reported a high
incidence shortly after renal transplantation (Fieren et al.,
2007; Balasubramaniam et al., 2009). This could either be
due to the acute cessation of PD or due to the profibrotic
effect of immunosuppressive medication (calcineurin inhibitors).
Calcineurin inhibitors, like Tacrolimus and Cyclosporin, cause
up-regulation of transforming growth factor-beta (TGF-β), and
other profibrogenic factors potentiating matrix accumulation
(Khanna et al., 2002). In experimental rat models, Cyclosporin
combined with chronic peritoneal exposure to dialysis solution
was associated with increased peritoneal fibrosis and angiogene-
sis (Van Westrhenen et al., 2007). However, the exact mechanism
of post-transplantation EPS still remains unknown.
Peritonitis is a common complication of PD and plays a com-
plex part in the development of EPS with the number of peritoni-
tis episodes linked to incidence of EPS (Yamamoto et al., 2005).
Recurrent peritonitis due to bacterial contamination includ-
ing Pseudomonas spp., Staphylococcus aureus, and certain fungal
organisms have been particularly implicated in the development
Table 1 | Non-peritoneal dialysis related causes of EPS.
• Autoimmune diseases
• Sarcoidosis
• Peritoneal and intra-abdominal malignancies
• Chronic peritoneal ascites
• Intra-peritoneal chemotherapy
• Intraperitoneal exposure to particulate matter or disinfectant
• Abdominal surgery
• Endometriosis
• Intra-peritoneal infections (tuberculosis)
• Beta-blocker administration
of EPS (Flanigan et al., 1984; Chew et al., 1997; Rigby and Hawley,
1998). Other risk factors suggested to be involved in EPS onset
are the composition of dialysis fluid and generation of GDPs,
young age, ultrafiltration failure and the exposure to PD catheter
cleaning reagent, chlorhexidine (Pollock, 2001) (Table 2).
CLINICAL FEATURES OF EPS
Patients usually present with abdominal symptoms like early
satiety, anorexia, nausea, vomiting, and altered bowel habit (con-
stipation or diarrhea in the early stages of EPS) (Nakamoto, 2005;
Augustine et al., 2009). These symptoms may be accompanied
by signs of inflammation (pyrexia and raised CRP) and/or blood
stained ascites in the early stages (Nakamoto, 2005; Maruyama
and Nakayama, 2008). Late stages of EPS are associated with
abdominal pain, fullness, overt bowel obstruction and presence
of an abdominal mass). This is caused by the development of
a fibrous cocoon that gradually covers the intestines and leads
to malnutrition, weight loss, bowel obstruction, ischemia and
strangulation, infection and death (Kawaguchi et al., 2000).
CLASSIFICATION OF EPS
Based on the clinical presentation, Nakamoto categorized EPS
into four groups (Nakamoto, 2005). The following are the pro-
posed clinical stages:
Stage 1- Pre-EPS stage: Asymptomatic with mild ascites and no
inflammation.
Stage 2- Inflammatory stage: Patients are symptomatic with
nausea and diarrhea consistent with partial encapsulation of
the bowel and intestinal swelling. Mild inflammation with
fibrin exudation is present.
Stage 3- Encapsulation: Symptoms of bowel obstruction due to
the formation of the fibrous cocoon causing encapsulation. It
can be associated with mild to severe inflammation.
Stage 4- Chronic stage of ileus: Patients have absolute bowel
obstruction caused by thickening of the encapsulating fibrous
cocoon. There is little, if any, inflammation at this stage.
DIAGNOSIS OF EPS
The diagnosis of EPS relies on clinical findings, radiological tests
and pathological appearance of the diseased tissue. Clinically, the
diagnosis of EPS is based on recognizing the signs and symptoms
(nausea, anorexia, early satiety, weight loss, altered bowel habit,
and ascites) in the patients at risk of developing the condition
(Nakamoto, 2005). Blood tests may also reveal high CRP and low
Table 2 | Risk factors for EPS in the peritoneal dialysis (PD)
population.
• Duration of PD
• Acute cessation of PD
• Organ transplantation
• Peritonitis
• Composition of dialysis fluid (low pH, high glucose)
• Young age
• Ultrafiltration failure
• Exposure to chlorhexidine
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albumin levels. These presenting symptoms and signs are vague
and non-localizing. However, the insidious nature and chronicity
of development can be a distinguishing feature of EPS (Kawaguchi
et al., 2000). As a consequence, EPS is often not recognized in its
early stages and requires a high index of suspicion to pursue a
diagnosis.
As the clinical picture of EPS can vary considerably, vari-
ous investigations are necessary to further evaluate a suspected
case (Kawaguchi et al., 2005). Ultrasonography, water-soluble
contrast studies and computed tomography (CT) scanning are
the most widely used radiological tests to aid the diagnosis of
EPS. CT scanning, however, is the investigation of choice in
patients with established EPS and helps monitor disease pro-
gression. Peritoneal enhancement, peritoneal thickening, calci-
fication, bowel tethering, bowel wall thickening, signs of bowel
obstruction, and loculated collections are the most common CT
findings of EPS (Vlijm et al., 2009). But, given the rare, complex
nature of the disease and with most of the CT scan appearances
being non-specific, interpretation and diagnosis can be difficult.
Surgery (Laparoscopy/Laparotomy and peritoneal biopsy) there-
fore may be needed to confirm the diagnosis (Kawaguchi et al.,
2005). At surgery, macroscopically, advanced cases of EPS typi-
cally exhibit a thickened brownish peritoneum with a cocoon-like
encapsulation of the entire intestine by the visceral peritoneum
(Figure 1). The intestinal loops are adherent to one another
and the visceral peritoneum is severely thickened with fibrosis.
Adhesions between the visceral and parietal peritoneum are rare,
except in cases of severe inflammation (Honda and Oda, 2005).
Macroscopic evidence of peritoneal calcification is also a feature
but is not necessarily present in all cases of EPS (Park et al.,
2008).
Numerous studies have been performed searching for poten-
tial biomarkers in PD effluent to aid the early diagnosis of EPS.
Low CA125 levels (denoting mesothelial cell loss) and high levels
of the inflammatory cytokine Interleukin-6 (IL-6) in PD effluent
have been noted several years before the diagnosis of EPS suggest-
ing that these factors could be potential early diagnostic markers
(Sampimon et al., 2010). However, further research is necessary
to identify definite biomarkers for early diagnosis of EPS. Current
imaging techniques are also not useful at reliably detecting EPS in
its early stages. CT scan screening of asymptomatic PD patients is
not recommended as EPSmay occur within a year of a normal CT
scan. Also, not all long-term PD patients with peritoneal abnor-
malities on CT go on to develop established EPS (Goodlad et al.,
2011). Dynamic cinematographic magnetic resonance (cine-MR)
scanning with advanced image analysis may be useful in early
detection of EPS. However, more studies are required to vali-
date the efficacy of this imaging modality (Wright et al., 2011).
Laparoscopy performed in suspected cases may have an impor-
tant role to play in the early diagnosis of EPS. Our current lack of
understanding of the pathophysiology limits our ability to detect
EPS early or prevent its occurrence.
HISTOLOGICAL FEATURES OF ENCAPSULATING
PERITONEAL SCLEROSIS
The two most relevant pathologies of long-term PD are
simple sclerosis and EPS. Simple sclerosis is characterized
FIGURE 1 | Macroscopic appearance of EPS at surgery. (A) Thickened
parietal peritoneum is held up by surgical clips. Visceral peritoneum is
thickened forming a fibrous cocoon encapsulating the bowel. (B) Visceral
peritoneum peeled off the small bowel which has a brownish, tanned
leathery appearance.
by the thickening of parietal peritoneum in the absence of
encapsulation. The uremic state and continuing PD leads to a
gradual loss of mesothelium (mesothelial denudation). Medial
sclerosis and hyalinization of the peritoneal vasculature (vascu-
lopathy) is also seen along with neoangiogenesis (Honda et al.,
1996). The sub-mesothelial compact zone thickens and is com-
posed of myofibroblasts and fibrous collagen (Mateijsen et al.,
1999). In addition, AGEs are found to be present in the mesothe-
lial and sub-mesothelial layer of PD patients (Yamada et al., 1994;
Nakayama et al., 1997). Of note the amount of angiogenesis
was found to be proportional to the severity of intestinal fibro-
sis (Mateijsen et al., 1999; Plum et al., 2001) and the level of
mesothelial deudation correlated with sub-mesothelial thicken-
ing and vasculopathy (Williams et al., 2003). Simple sclerosis is
a fairly common finding in long-term PD patients while EPS is
rare. Therefore, studies analysing the histological differences in
the peritoneum from EPS and simple sclerosis patients are lim-
ited. Of these, only one study performed by Garosi et al. (2005)
analyzed both visceral and parietal peritoneum, and Braun and
colleagues analyzed only visceral peritoneum (Braun et al., 2012)
while the remaining studies did not specify the type of peri-
toneum analyzed (Table 3). Garosi and colleagues investigated
180 peritoneal biopsies of PD patients with simple sclerosis and
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Table 3 | Comparative histopathology of EPS patients and non-EPS PD patients.
Braun et al., 2012 Braun et al., 2009 Sherif et al., 2008 Garosi et al., 2005 Honda et al., 2003
EPS patients (n) 31 9 12 39 12
Non-EPS PD patients (n) 27 10 30 180 57
Visceral (V) or parietal (P) – V – V and P –
Histologic parameters Significance between EPS and non-EPS PD patients
Fibrosis S S S – NS
Degenerated layer thickness – – S – –
Fibroblast like cells S – – – –
Inflammation NS – – S S
Mesothelial denudation S – NS – NS
Vasculopathy NS S – S NS
Fibrin deposition S – S – S
Vessel density NS S – – –
Fe deposits S – – – –
Decreased cellularity S – – – –
Fibroblast enlargement – – – – S
Capillary angiogenesis – – – – S
Calcification NS – – S –
(S) and (NS) denote significance and non-significance, respectively. (–) denotes data not being measured or recorded.
compared morphological findings with those from biopsies of
39 patients with EPS (Garosi et al., 2005). Significant findings
in patients with EPS were thickening of the sub-mesothelial cell
layer, vasculopathy, arterial occlusion, inflammation, tissue and
arterial calcification, and ossification. In a similar study, fibrin
deposition, increase in the size of fibroblasts, capillary angiogene-
sis, andmononuclear cell infiltration weremore common features
of EPS than simple sclerosis (Honda et al., 2003). Sherif and col-
leagues compared the peritoneum of EPS with simple sclerosis
and showed that the sub-mesothelial compact zone was thin-
ner in early-EPS than late-EPS (Sherif et al., 2008). In a more
recent study, fibroblast-like cells, mesothelial denudation, calcifi-
cation, decreased cellularity and positive iron staining were more
common in the peritoneum of EPS patients. Positive immuno-
histochemical staining for podoplanin, a lymphatic endothelial
marker expressed by peritoneal mesothelial cells, was signifi-
cantly more prevalent in EPS peritoneum (Braun et al., 2012).
Up-regulation of vascular endothelial growth factor (VEGF) and
down-regulation of mast cells (Alscher et al., 2007; Braun et al.,
2009) also appeared to be a feature of EPS peritoneum. However,
as the above findings are not always specific to EPS tissue, reliable
histological diagnosis is difficult. Further studies are therefore
necessary to explore the presence of additional unique immuno-
histochemical markers to aid the diagnosis.
PATHOPHYSIOLOGY OF ENCAPSULATING PERITONEAL
SCLEROSIS
Although a number of risk factors have been identified, there are
currently no means of preventing EPS development or recogniz-
ing earlier stages of the disease. Furthermore, it is a matter of
debate whether EPS is a natural progression of simple sclerosis or
a completely separate entity. However, it is clear that having sim-
ple sclerosis does not predispose to developing EPS. It is generally
now accepted that a two-hit theory explains EPS development.
It is well established that chronic exposure to bio-incompatible
dialysate causes damage to the peritoneum of all patients on PD.
This first hit causes mesothelial disruption which can trigger a
fibrotic process which is referred to as “simple sclerosis.”
The subsequent exposure to a second insult, in some patients,
triggers the development of EPS. This can be either an episode
of peritonitis, acute cessation of PD, transplantation, any other
acute intra-abdominal event or maybe a genetic predisposition
(Figure 2). A number of genetic polymorphisms with functional
effects have been described in patients on PD and these may
partially explain the propensity to develop EPS (Pletinck et al.,
2012). A number of rodent models of EPS have been developed
using chronic chemical irritation to induce peritoneal sclerosis
and bowel encapsulation (Hoff, 2005; Summers et al., 2008). Such
models replicate the cycles of tissue injury with fibrin deposition
and inflammation leading to subsequent repair with mesothelial
cell and fibroblast activation, proliferation and matrix deposi-
tion that are proposed to drive the development of EPS. Some
of these mechanisms of induction are described in more detail
below.
INFLAMMATORY PROFILE
The PD catheter can itself trigger inflammation either directly as
a foreign material or by acting as a site of bacterial biofilm for-
mation leading to PD peritonitis (Flessner et al., 2007). Various
characteristics of PD fluid such as low pH, high glucose lev-
els, hyperosmolarity, presence of GDPs, and AGEs promote the
release of several growth factors such as Transforming Growth
Factor-β (TGF-β) and Platelet Derived Growth Factor (PDGF)
and pro-inflammatory cytokines, IL-1, IL-6, IL-18, and Tumor
Necrosis Factor-alpha (TNF-α) potentiating fibrosis (Margetts
and Bonniaud, 2003; Baroni et al., 2012).
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FIGURE 2 | Proposed pathogenesis of EPS: “Two-hit” theory (Modified
from Augustine et al., 2009). AGE, Advanced Glycation End-products; RAGE,
Receptors for Advanced Glycation End-products; IL-1, Interleukin-1; TNF, Tumor
Necrosis Factor; TGF-β, Transforming Growth Factor-β; VEGF, Vascular
EndothelialGrowthFactor; EMT,Epithelial toMesenchymal Transdifferentiation;
MMP, Matrix Metalloproteinases; ECM, Extracellular Matrix.
Clinical studies have found elevated levels of IL-1β, IL-6, IL-
8, TGF-β1, Hepatocyte Growth Factor (HGF), and PDGF in
ascites from EPS patients in comparison with non-EPS controls
(Masunaga et al., 2003). As EPS develops, patients also suffer
from subclinical bowel ischemia which may cause translocation
of bacteria across the bowel wall into the peritoneal cavity leading
to infection, further inflammation and fibrosis (Augustine et al.,
2009).
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FIBRIN DEPOSITION AND FIBRINOLYSIS
Peritoneal inflammation initiates fibrin exudation that can either
be lysed or remodeled by invading fibroblasts leading to fibro-
sis and adhesion formation (Holmdahl, 1997; Sulaiman et al.,
2002). Plasmin plays a key role not only in fibrin degradation
but also in the turnover of extracellular matrix and activation
of matrix metalloproteinases. Plasmin is formed from the inac-
tive zymogen plasminogen under the influence of plasminogen
activators: tissue plasminogen activator (tPA) and urokinase-like
plasminogen activator (uPA), whereas, plasminogen activation
inhibitors (PAI-1 and PAI-2) reduce plasminogen activation. Low
levels of plasmin and high levels of PAI were found in serum
of patients on PD compared with hemodialysis (HD) patients
suggesting a higher degree of hypercoagulation (Tomura et al.,
1996). Mesothelial cells express PAI-1 and 2 under the influence
of TGF-β (Rougier et al., 1998; Holmdahl et al., 2001) and such an
inappropriate balance between fibrin deposition and breakdown
increases the probability of fibrous adhesion formation possibly
contributing to the development of EPS.
EPITHELIAL–MESENCHYMAL TRANSITION (EMT) OF MESOTHELIAL
CELLS
In terms of peritoneal fibrosis, substantial evidence points to
mesothelial cells (MCs) as being the principle source of myofi-
broblasts via a process of epithelial–mesenchymal transition
(EMT) (Aroeira et al., 2007). MCs are unique in their expression
of both epithelial and mesenchymal markers, and when exposed
to injurious agents, they lose cell-cell contact and apical-basal cell
polarity and invade the basal lamina changing to a mesenchy-
mal phenotype expressing α-smooth muscle actin and depositing
extracellular matrix (Aguilera et al., 2005). EMT occurs during
normal embryo development and tumor cell invasion and metas-
tasis and is a complex process that requires the correct spatiotem-
poral expression, interaction and modification of a multitude of
intra-and extracellular factors to allow a change in cell phenotype
(Thiery et al., 2009). Loss of cell surface E-cadherin is a prereq-
uisite for EMT and primarily controlled by three main families
of transcription factors: zinc finger Snail, basic helix-loop-helix,
and ZEB (Kalluri and Weinberg, 2009). Several groups have
shown the presence of mesothelial markers (ICAM-1 and cytok-
eratin) localized with spindle-shaped fibroblast- like cells in the
sub-mesothelial layer in peritoneal biopsies from patients under-
going PD suggesting EMT had occurred (Yanez-Mo et al., 2003;
Jimenez-Heffernan et al., 2004). Mesothelial cells isolated from
dialysis fluid effluents from patients undergoing peritoneal dialy-
sis also undergo a transition from epithelial to mesenchymal with
a loss of E-cadherin (Zhang et al., 2013) and induction of snail
(Yanez-Mo et al., 2003). Furthermore, AGE products (De Vriese
et al., 2006) and dialysate (Selgas et al., 2006) induce human
mesothelial EMT in culture. The process of EMT can occur under
the influence of a number of pro-inflammatory and profibrotic
cytokines, however TGF-β is proposed to be a principle mediator
of mesothelial EMT as demonstrated both in vitro (Hung et al.,
2003; Yang et al., 2003) and in vivo (Margetts et al., 2005). In
terms of therapeutic strategy, blocking TGF-β1 (Loureiro et al.,
2011), or addition of tamoxifen (Loureiro et al., 2013a) bone
morphogenic protein-7 (Yu et al., 2009), or microRNA30a (Zhou
et al., 2013) have all been found to protect the peritoneum from
dialysate—induced damage in experimental models. Although
strong evidence suggests that mesothelial EMT is important for
the development of peritoneal sclerosis, the role this process plays
in EPS, is a matter of debate (Loureiro et al., 2013b).
GROWTH FACTORS POTENTIALLY INVOLVED IN THE DEVELOPMENT OF
EPS
The pathways involved in the development of EPS are likely to
be complex and involve the interaction of a number of important
growth factors leading to sub-mesothelial thickening and cocoon-
ing of the bowels. The level of the pro-neoangiogenic growth
factor, Vascular Endothelial Growth Factor (VEGF), detected
in peritoneal effluent has been found to directly correlate with
length of time the patients are on PD (Zweers et al., 2001).
Furthermore, treatment with VEGF blocking antibody reduced
the thickness of the sub-mesothelial layer and reduced vasculopa-
thy in a rat model of EPS (Io et al., 2004) suggesting a key role
for this factor in EPS development. VEGF is produced by cul-
tured human peritoneal mesothelial cells in response to various
stimuli such as GDPs known to be present in PD fluid (Mandl-
Weber et al., 2002). TGF-β, another important growth factor in
wound healing and fibrosis, has also been shown to be present
in peritoneal dialysate from patients (Lin et al., 1998; Yanez-
Mo et al., 2003) Exposure of human mesothelial cells to TGF-β1
induced procollagen type 1 expression (Hung et al., 2003) and in
rodent models, TGF-β1 administration caused peritoneal fibrosis
(Margetts et al., 2005), and adhesion formation (Williams et al.,
1992; Gorvy et al., 2005). Moreover, studies in a hyperglycemia-
induced rodent model showed that AGEs upregulate TGF-β and
induce submesothelial fibrosis with interstitial accumulation of
collagen (De Vriese et al., 2003). Furthermore, intraperitoneal
administration of a first generation adenovirus overexpressing
TGF-β1 in mice resulted in submesothelial thickening and angio-
genesis up to 10 days after administration (Margetts et al., 2005).
However, a helper dependent adenovirus subsequently used with
longer term expression of TGF-β1 led to encapsulation of the
bowels in a thick cocoon in a similar manner to the final stages
of EPS (Liu et al., 2009). Over-expression of TGF-β also increased
levels of matrix metalloproteinase-2 (MMP-2) and high amounts
of this protease found in PD effluent has been considered a poten-
tial marker of peritoneal injury and progression to EPS (Hirahara
et al., 2007). In a mouse model, inhibition of MMP-2, TGF-β, and
VEGF significantly improved peritoneal fibrosis and angiogene-
sis (Ro et al., 2007). Many other growth factors including HGF,
PDGF, Connective Tissue Growth Factor (CTGF), and Fibroblast
Growth Factor (FGF), shown to be involved in the development
of fibrosis in other organs, may also influence the onset of EPS
(Korte et al., 2011a).
THERAPEUTIC MANAGEMENT OF EPS
DISCONTINUATION OF PD
Cessation of PD should be done as soon as the diagnosis of EPS
has been established. However, as cessation of PD is a known risk
factor for the development and progression of EPS, this approach
has been under much debate. Regular peritoneal lavage after dis-
continuation of PD has been tried in Japan with varying results. A
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recent retrospective study performed by Yamamoto et al. (2010)
has demonstrated that regular peritoneal lavage helps mesothelial
cell layer recovery and prevention of EPS. However, given the risk
of peritonitis with peritoneal lavage and the increased association
of peritonitis and prolonged PD therapy with EPS progression,
it is best to stop PD at the time of diagnosis of EPS along with
removal of the PD catheter (Habib et al., 2011; Kawanishi, 2012).
NUTRITIONAL SUPPORT
As most patients with EPS suffer from malnutrition, appro-
priate nutritional support is imperative in the management
of these patients. Studies from our centre have demonstrated
poor pre-operative nutritional status and improved survival
with peri-operative Total Parenteral Nutrition (TPN) in patients
with advanced EPS who underwent surgery (peritonectomy
and enterolysis) (De Freitas et al., 2007; Campbell et al.,
2014). However, TPN therapy on its own does not have
any curative effect as demonstrated by a study from Japan
which showed no recovery in patients treated with TPN alone
(Kawanishi and Moriishi, 2005). TPN therapy is therefore
best used as an adjunct to more definite treatment in EPS
patients with malnutrition or peri-operatively until gut function
recovers.
MEDICAL TREATMENT
The evaluation of the efficacy of pharmacological treatments for
EPS is difficult due to the lack of good evidence based data.
However, the treatment options currently in vogue are as follows:
Immunosuppressive therapy
Corticosteroids are the drugs of choice in the management of
EPS. They are particularly useful in the treatment of EPS in
its early inflammatory stages (Kuriyama and Tomonari, 2001;
Kawanishi, 2012). Steroids possibly act by suppressing inflam-
mation, preventing fibrin deposition and collagen synthesis and
maturation (Habib et al., 2011). Steroids also help in prevent-
ing the formation and reducing the accumulation of ascites (Mori
et al., 1997; Jung and Cho, 2013). Various case reports and series
have reported good prognosis and improved survival with the
use of steroids compared to any other immunosuppressive agent
(Junor and McMillan, 1993; Rajani, 2002). However, in a study
from Japan, the rate of clinical improvement with isolated steroid
treatment was only 38.5% (Kawanishi et al., 2004). Nevertheless,
steroids are effective in treating the early stages of EPS but the
clinical response tends to reduce in the later stages that are
associated with increased fibrosis and bowel obstruction. A vari-
ety of other immunosuppressive medications like azathioprine,
rapamycin, mycophenalate mofetil, sirolimus, and cyclosporine
have also been used to treat EPS either alone or in combination
with steroids (Rajani, 2002; Wong et al., 2005; Lafrance et al.,
2008). However, apart from steroids, evidence regarding the effi-
cacy of any other immunosuppressive therapy in EPS remains
weak due to lack of robust randomized clinical trials (Bozkurt
et al., 2009).
Tamoxifen
Tamoxifen is a Selective Estrogen Receptor Modulator (SERM)
with antifibrotic properties and has been used in the treatment
of various fibrotic disorders like retroperitoenal fibrosis, fibrosing
mediastinitis, fibrosing cerivicitis, and desmoid tumors (Cornelis
and Oreopoulos, 2011). Various case reports and small series have
reported satisfactory outcomes following the use of Tamoxifen
in the treatment of EPS (Guest, 2009; Cornelis and Oreopoulos,
2011). A recent large retrospective Dutch study has demonstrated
significantly reduced mortality in EPS patients that were treated
with Tamoxifen (45.8%) when compared to those that were not
treated with Tamoxifen (74.4%) (Korte et al., 2011b). Tamoxifen
appears to exert its effect through inhibition and modulation
of TGF-β. In vitro and animal models showed that Tamoxifen
treatment blocked EMT induced by TGF-β, preserved the fibri-
nolytic activity and reduced the migration capacity of mesothelial
cells leading to reduced fibrosis and reduced PD effluent lev-
els of VEGF leading to reduced angiogenesis in the peritoneum
(Loureiro et al., 2013a). However, Tamoxifen has almost always
been used in combination with corticosteroids, therefore the effi-
cacy and safety of Tamoxifen alone in the treatment of EPS still
remains to be evaluated. The potential side-effects of Tamoxifen
(deep vein thrombosis, endometrial cancer, and calciphylaxis)
also need to be considered (Del Peso et al., 2003). Further
prospective trials are therefore necessary to establish the safety
and efficacy of Tamoxifen in the treatment of EPS.
SURGERY
Surgical techniques in the management of EPS have evolved
over the last decade. Surgery is routinely performed in patients
with advanced EPS in Japan and in the UK at specialist refer-
ral centers by surgeons experienced in the management of EPS
(Augustine et al., 2009; Kawanishi, 2012). Surgery is usually per-
formed in the late stages of EPS, in patients that present with
absolute bowel obstruction or as surgical emergencies with an
acute abdomen. Currently favored surgical techniques are peri-
tonectomy and careful enterolysis which involves resection of the
peritoneum and fibrous tissue together with division of adhesions
to release the bowel (Figure 1). Mortality post-surgery ranges
from 19 to 34.5% (Summers et al., 2005; Kawanishi, 2012; Latus
et al., 2013) and is mainly seen in patients with advanced EPS pre-
senting as surgical emergencies (Augustine et al., 2009). Although
surgery is the most successful form of treatment for patients with
advanced disease, recurrence rates post-surgery tend to be high
at around 25%. However, in Japan, the recent introduction of
Noble plication (suturing of the intestines to each other to prevent
obstruction) along with routine enterolysis has reduced the recur-
rence rate to 12.3% (Kawanishi, 2012). Tamoxifen and steroids
may also be continued post-operatively as they may have a role in
preventing recurrence of EPS (Lo and Kawanishi, 2009).
PREVENTION
Although various studies have demonstrated possible mecha-
nisms in the development of EPS, we still have no strategy to
prevent the occurrence of this condition. As the risk of devel-
oping EPS increases with the duration of PD, there has been
much debate on an “expiry date” for PD in patients. Studies
from Japan have suggested 8 years to be a safe period to continue
PD beyond which patients should be switched to hemodialy-
sis (Kawanishi et al., 2004). However, setting an expiry date is
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not recommended as it could have a negative impact on the
quality of life and could increase the risk of complications of
tunneled lines used for hemodialysis in patients who were symp-
tom free on PD (Garosi et al., 2005). A more rational approach
would be to assess peritoneal membrane function. The commonly
used method to assess peritoneal deterioration is the Peritoneal
Equilibration Test (PET) with a high transport of solutes across
the peritoneal membrane being indicative of failing function.
There has been a suggestion of cessation of PD in all patients
that show a high transport status (Kawanishi, 2012). However,
not all patients that are high transporters develop EPS. Therefore,
this approach has been under much debate. Peritoneal lavage
could potentially be used in patients who have been on long-
term PD (>8 years), with high transport status and increased
levels of markers of inflammation (IL-6) and low levels of Ca-
125 in their PD effluent in order to delay the development of
EPS (Moriishi et al., 2002). However, this approach is not univer-
sally practiced due to the associated risk of infective peritonitis.
Other proposed methods of possible prevention are by using
more bio-compatible PD fluid and taking care to reduce the
incidence of infective peritonitis. Addition of therapeutic agents
such as, Tamoxifen and Angiotensin Converting Enzyme (ACE)
inhibitors, may show promise to ameliorate peritoneal membrane
function and fibrosis (Kolesnyk et al., 2007). Further studies are
therefore necessary to investigate possible therapeutic strategies to
prevent the exacerbated fibrotic process which culminates in EPS.
CONCLUSION
Despite the increase in incidence and awareness over the last
decade, EPS still remains a rare but much feared complication
of long-term PD. Prolonged PD therapy is the most important
risk factor in the development of EPS. Uremia, inflammation,
EMT and loss of mesothelial fibrinolytic response are possi-
ble mechanisms of peritoneal fibrosis which could influence the
development of EPS. However, the aetiopathogenesis still remains
poorly understood. Currently a high index of suspicion in at
risk groups is required to make the diagnosis of EPS. CT scan
is the investigation of choice to aid the diagnosis, but the use
of newer imaging modalities like cine-MRI, that shows promis-
ing signs, still needs to be validated. Low levels of Ca-125 and
high levels of IL-6 in PD effluent have been suggested as early
markers of development of EPS. However, further research needs
to be done to validate this claim and look for other poten-
tial bio-markers to detect EPS early. The treatment of EPS in
its early stages is largely medical with corticosteroids, tamoxifen
and nutritional support. However, surgery (peritonectomy and
enterolysis) is the treatment of choice for advanced cases pre-
senting with overt bowel obstruction. Peri-operative nutritional
support with TPN and post-operative steroids with or without
Tamoxifen is recommended to prevent recurrence. Improvement
in surgical technique has vastly improved survival of patients with
EPS. However, despite successful surgery these patients remain
at increased risk of mortality due to ongoing renal replacement
therapy. Many clinicians are reticent toward transplantation in
these patients due to a perception that transplantation might
not be feasible given the complex surgical history. Although, the
risk of developing recurrent disease post transplantation exists,
the chances of survival are much improved with a functioning
kidney transplant. These patients should therefore be assessed
and worked up for renal transplantation in order to improve
long-term survival.
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